MediWound Ltd.

NasdaqGM MDWD

MediWound Ltd. Gross Profit Margin for the year ending December 31, 2023: 19.15%

MediWound Ltd. Gross Profit Margin is 19.15% for the year ending December 31, 2023, a -61.46% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

MediWound Ltd. Gross Profit Margin for the year ending December 31, 2022 was 49.69%, a 34.61% change year over year.
MediWound Ltd. Gross Profit Margin for the year ending December 31, 2021 was 36.91%, a 6.47% change year over year.
MediWound Ltd. Gross Profit Margin for the year ending December 31, 2020 was 34.67%, a -44.73% change year over year.
MediWound Ltd. Gross Profit Margin for the year ending December 31, 2019 was 62.73%, a 62.48% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: MDWD

MediWound Ltd.

CEO	Mr. Ofer Gonen B.Sc.
IPO Date	March 20, 2014
Location	Israel
Headquarters	42 Hayarkon Street
Employees	100
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Key trends

Past 5 years